- Cybin Inc. today announced its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market.
- Cybin will commence trading on the OTCQB with the market open on March 8, 2021, under the symbol “CLXPF.”
Cybin Inc. (CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). Cybin will commence trading on the OTCQB with the market open on March 8, 2021, under the symbol “CLXPF”.
The OTCQB, operated by OTC Markets Group Inc., is designed for developing and entrepreneurial companies in the United States and abroad. Companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities.
“Listing on the OTCQB is another important milestone for Cybin. It affords us greater visibility within the investment community, which should enhance our liquidity and increase our access to institutional and retail investors. This additional capital markets exposure will be valuable, as we continue to support our psychedelic drug development programs to potentially treat mental health disorders, such as Major Depressive Disorder and other therapy-resistant psychiatric disorders.”
Doug Drysdale – CEO of Cybin
The Company would also like to announce a new strategic brand messaging campaign designed to align its corporate mission amongst the investor community across North America and Europe. The Company will continue to engage investor communications, financial research, and cross platform digital marketing service providers to increase public awareness regarding corporate activities, strategic plans, and the investment opportunity through the dissemination of Company information extrapolated from publicly disclosed investor presentations and press releases.
The Company has engaged CDMG INC. to develop and execute a comprehensive investor relations program and to provide marketing services focusing on North America and Europe.
Cybin will continue to trade on the NEO Exchange under its existing symbol “CYBN.”
About Cybin
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.